CandiReg registry for invasive Candida infections
Part of Infections clinical trials.
This study is a hospital registry that collects health and test information about people with confirmed invasive Candida (a fungal infection). It may help doctors understand who gets these infections and how they spread, which can improve future diagnosis and care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have evidence of invasive Candida infection based on tests like tissue exam (histopathology), antigen tests, or DNA tests
- If you have hepatosplenic Candida infection, you must also have signs that the infection spread through the body
- Your case will be included as part of a case group, and other hospitals may be involved for comparisons
- You are likely compared with a control patient matched by age/demographics, other illnesses, risk factors, and hospital stay time
- Your infection must be invasive or disseminated—not just surface-level or colonization
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study enrolls people who have test results showing an invasive fungal infection (a fungus causing illness inside the body). The goal is to build a global registry to better understand these infections and improve future care.
This study looks at patients in the intensive care unit who have a new infection with Candida (a type of fungus) despite taking strong antibiotics. It aims to better understand and diagnose these serious infections.
This study looks at how Candida infections form biofilms (protective coatings) and resist antifungal treatments. It may help find better ways to treat serious Candida infections in people with weakened immune systems or after medical procedures.
This study collects medical information and optional biological samples (like blood or saliva) from people with an active or suspected infection. The goal is to build a large database that can help researchers better understand infectious diseases and develop new ways to diagnose and treat them.
This trial tests a new antifungal drug, HRS9432, for patients with candidemia (a yeast infection in the blood) or invasive candidiasis (yeast infection in organs). It aims to see if the drug is safe and works well for these serious infections.
This study looks at how immune system problems relate to fungal infections, using medical records and lab tests on blood and tissue. It may help researchers understand the cause of these infections—especially for people with inherited immune conditions—and improve future care.
Hear when a new Invasive Candidiases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.